FINANCE & SPEND cost of ownership metrics, treating lower carbon intensity as a product differentiator for hospital and healthsystem purchasers.
The leadership case for resilience The leadership case helps land the change internally.“ The momentum across our company is continuing in 2026 …” Chief Executive Pascal Soriot recently told investors, underlining how sustainability and pipeline performance are being presented as complementary drivers of long-term resilience. At the supplier level, Jenny Perrie, AstraZeneca’ s Scope 3 lead in Global Procurement, sums up the procurement imperative:“ Our Scope 3 footprint is more than 20 times greater than our Scope 1 and 2 footprint and our ambitions will only be achieved through close collaboration with our supply chain partners.”
For procurement leaders in pharma, AstraZeneca offers a practical blueprint: treat category management as decarbonisation infrastructure, make supplier transition measurable and invest in supplier capability. The result is not just a cleaner balance sheet, it’ s a stronger product proposition for customers whose own sustainability obligations increasingly shape purchasing decisions.
procurementmag. com
111